Pegmolesatide

培莫沙肽

Report date: 2024/03/06 15:48:26
NME

Base Information

Drug NamePegmolesatide
Drug Alias Name培化西海马肽Pegol SihematidePeihuaxi hippocampal peptidepegmolesatidePegol-Sihematide +[7] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsMyelodysplastic SyndromesAnemiaRenal Insufficiency, Chronic +[4] 
Global Approved IndicationsAnemiaRenal Insufficiency, Chronic
Approved Indications in ChinaAnemiaRenal Insufficiency, Chronic
Original Approved Country/TerritoryMainland China
Original Approved Date2023/06/30
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hansoh Pharmaceutical Group Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Hansoh Pharmaceutical Group Co Ltd
Inactive CompaniesShanghai Hansoh Biomedical Co Ltd
Active IndicationsMyelodysplastic SyndromesAnemiaRenal Insufficiency, Chronic
Inactive IndicationsRenal Insufficiency

Other Information

ATC CodeN/A
Related LinksN/A